Advertisement

Endocrine

, Volume 46, Issue 3, pp 406–419 | Cite as

Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature

  • Carlo B. GiordaEmail author
  • Elisa Nada
  • Barbara Tartaglino
Review

Abstract

Renal or hepatic impairment, often encountered in patients with type 2 diabetes, influences the pharmacokinetics and bioavailability of antihyperglycemic agents. An emerging concern is whether pharmacotherapy with incretin-based agents, the most recent drug classes to be introduced for type 2 diabetes, can be safely used in patients with renal insufficiency or hepatic damage. This literature review examines the results of studies on these novel drug classes, with a view to provide the practitioner with a balanced, evidence-based position when considering incretin-based therapies in patients with type 2 diabetes and impaired kidney or liver function. All currently available dipeptidyl peptidase-4 (DPP-4) inhibitors appear to be appropriate pharmacotherapeutic choices in patients with declining renal function, with linagliptin affording the added advantage of not requiring dose adjustment or periodic monitoring of drug-related kidney function. In contrast, caution is warranted with the use of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with moderate or severe renal impairment. The slightly wider evidence base for liraglutide than for exenatide or lixisenatide is not sufficient to support its use in severe renal impairment. What little evidence there is for incretin-based therapies in hepatic impairment has come from a few past hoc analysis of clinical trials, with most precautions and warnings reflecting the paucity of knowledge about incretin efficacy or safety in this condition.

Keywords

Incretins or DPP-4 inhibitors or GLP-1 receptor agonists Safety Efficacy Renal impairment Hepatic impairment 

Notes

Conflict of interest

CBG discloses teaching and speaking fees from Merck, Novo Nordisk, BMS/AZ Alliance, and BI/Lilly Alliance. All the other authors declare no conflicts of interest.

References

  1. 1.
    KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007; 49 (2 Suppl 2): S12-154Google Scholar
  2. 2.
    C.E. Koro, B.H. Lee, S.J. Bowlin, Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin. Ther. 31(11), 2608–2617 (2009)PubMedCrossRefGoogle Scholar
  3. 3.
    J.L. Meyers, S.D. Candrilli, B. Kovacs, Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment. Postgrad. Med. 123(3), 133–143 (2011)PubMedGoogle Scholar
  4. 4.
    National Diabetes Fact Sheet 2011. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Atlanta, GAGoogle Scholar
  5. 5.
    G. Penno, A. Solini, E. Bonora, C. Fondelli, E. Orsi, G. Zerbini, R. Trevisan, M. Vedovato, G. Gruden, F. Cavalot, M. Cignarelli, L. Laviola, S. Morano, A. Nicolucci, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. J. Hypertens. 29(9), 1802–1809 (2011)PubMedCrossRefGoogle Scholar
  6. 6.
    G. Pugliese, A. Solini, C. Fondelli, R. Trevisan, M. Vedovato, A. Nicolucci, Penno G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. Reproducibility of albuminuria in type 2 diabetic subjects. Findings from the Renal Insufficiency And Cardiovascular Events (RIACE) study. Nephrol. Dial. Transplant. 26(12), 3950–3954 (2011)PubMedCrossRefGoogle Scholar
  7. 7.
    G.L. Bakris, Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clin. Proc. 86(5), 444–456 (2011)PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    S.K. Majumdar, S.E. Inzucchi, Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy? Endocrine 44(1), 47–58 (2013)PubMedCrossRefGoogle Scholar
  9. 9.
    Dejager S, Schweizer A. Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment. Hosp Pract (1995). 2012 Apr;40(2):7-21Google Scholar
  10. 10.
    N.V. Niemeyer, L.M. Janney, Thiazolidinedione-induced edema. Pharmacotherapy 22, 924–929 (2002)PubMedCrossRefGoogle Scholar
  11. 11.
    A.J. Krentz, R.E. Ferner, C.J. Bailey, Comparative tolerability profiles of oral antidiabetic agents. Drug Saf. 11(4), 223–241 (1994)PubMedCrossRefGoogle Scholar
  12. 12.
    Aires Neto P, Gomes HV, Campos M. Management of hyperglycemia in patients with chronic kidney disease. J Nephrol. 2013 Jul-Aug;26(4):629-35Google Scholar
  13. 13.
    I. Mühlhauser, G. Toth, P.T. Sawicki, M. Berger, Severe hypoglycemia in type I diabetic patients with impaired kidney function. Diabetes Care 14, 344–346 (1991)PubMedCrossRefGoogle Scholar
  14. 14.
    H.B. El-Serag, T. Tran, J.E. Everharts, Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126, 460–468 (2004)PubMedCrossRefGoogle Scholar
  15. 15.
    P.S. Hsieh, Y.J. Hsieh, Impact of liver diseases on the development of type 2 diabetes mellitus. World J. Gastroenterol. 17(48), 5240–5245 (2011)PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    I. Balik, N. Yilmaz, N. Turkcapar, H. Yasa, Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 30, 584 (1999)PubMedCrossRefGoogle Scholar
  17. 17.
    D.J. Drucker, S.I. Sherman, F.S. Gorelick, R.M. Bergenstal, R.S. Sherwin, J.B. Buse, Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 33(2), 428–433 (2010)PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    C.F. Deacon, Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes. Metab. 13(1), 7–18 (2011)PubMedCrossRefGoogle Scholar
  19. 19.
    J.A. Davidson, J. Brett, A. Falahati, D. Scott, Mild renal impairment and the efficacy and safety of liraglutide. Endocr Pract 17(3), 345–355 (2011)PubMedCrossRefGoogle Scholar
  20. 20.
    A.J. Scheen, Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes. Metab. 12(8), 648–658 (2010)PubMedCrossRefGoogle Scholar
  21. 21.
    Saxagliptin Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001039/WC500044316.pdf. Last access January 8, 2014
  22. 22.
    Linagliptin Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002110/WC500115745.pdf. Last access January 8, 2014
  23. 23.
    Sitagliptin Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000722/WC500039054.pdf. Last access January 8, 2014
  24. 24.
    Vildagliptin Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000771/WC500020327.pdf. Last access January 8, 2014
  25. 25.
    R. Christopher, P. Covington, Davenport M.P. Fleck, Q.A. Mekki, E.R. Wann, A. Karim, Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin. Ther. 30, 513–527 (2008)PubMedCrossRefGoogle Scholar
  26. 26.
    P. Covington, R. Christopher, M. Davenport, P. Fleck, Q.A. Mekki, E.R. Wann, A. Karim, Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin. Ther. 30, 499–512 (2008)PubMedCrossRefGoogle Scholar
  27. 27.
    Capuano A, Sportiello L, Maiorino MI, Rossi F, Giugliano D, Esposito K. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin. Drug Design, Development and Therapy 2013:7 989–1001Google Scholar
  28. 28.
    Exenatide Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000698/WC500051845.pdf. Last access January 8, 2014
  29. 29.
  30. 30.
    U. Graefe-Mody, C. Friedrich, A. Port, A. Ring, S. Retlich, T. Heise, A. Halabi, H.J. Woerle, Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes. Metab. 13(10), 939–946 (2011)PubMedCrossRefGoogle Scholar
  31. 31.
    Friedrich C, Emser A, Woerle HJ, Graefe-Mody U. Renal Impairment Has No Relevant Effect on Long-Term Exposure of Linagliptin in Patients With Type 2 Diabetes Mellitus. 71st Scientific Sessions of the American Diabetes Association, San Diego, California, June 24–28, 2011. Poster: 1105-PGoogle Scholar
  32. 32.
    D.W. Boulton, L. Li, E.U. Frevert, A. Tang, L. Castaneda, N.N. Vachharajani, D.M. Kornhauser, C.G. Patel, Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin. Pharmacokinet. 50(4), 253–265 (2011)PubMedCrossRefGoogle Scholar
  33. 33.
    D. Boulton, A. Tang, C. Patel et al., Pharmacokinetics of the dipeptidyl peptidase-4 inhibitor saxagliptin in subjects with renal impairment. Endocrine Abstracts 20, P357 (2009)Google Scholar
  34. 34.
    A.J. Bergman, J. Cote, B. Yi, T. Marbury, S.K. Swan, W. Smith, K. Gottesdiener, J. Wagner, G.A. Herman, Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 30, 1862–1864 (2007)PubMedCrossRefGoogle Scholar
  35. 35.
    A. Karim, P. Fleck, L. Hetman et al., Single-dose pharmacokinetics of the dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment (Abstract 538-P). Diabetes 57(Suppl. 1), A160 (2008)Google Scholar
  36. 36.
    Y.L. He, B. Flannery, Y. Wang et al., The influence of renal impairment on pharmacokinetics of vildagliptin (Abstract PIII-86). Clin. Pharmacol. Ther. 81(Suppl. 1), S113 (2007)Google Scholar
  37. 37.
    Arjona Ferreira JC, Yu Q, Golm G, McCrary Sisk C, Williams-Herman D. High Correlation between Estimated Glomerular Filtration Rate and Estimated Creatinine Clearance for Sitagliptin Dose Selection in Patients with Renal Insufficiency. 2011 ADAGoogle Scholar
  38. 38.
    H. Linnebjerg, P.A. Kothare, S. Park, K. Mace, S. Reddy, M. Mitchell, R. Lins, Effect of renal impairment on the pharmacokinetics of exenatide. Br. J. Clin. Pharmacol. 64(3), 317–327 (2007)PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    L.V. Jacobsen, C. Hindsberger, R. Robson, M. Zdravkovic, Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br. J. Clin. Pharmacol. 68(6), 898–905 (2009)PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Liu YH, Ruus P. Pharmacokinetics and safety of the GLP-1 agonist AVE0010 in patients with renal impairment. Diabetes. 2009;58(Suppl. 1):Abstract 557-PGoogle Scholar
  41. 41.
    Graefe-Mody U, Rose P, Retlich S, Ring A, Waldhauser L, Cinca R, Woerle HJ. Pharmacokinetics of linagliptin in subjects with hepatic impairment. Br J Clin Pharmacol. 2012 Jan 13Google Scholar
  42. 42.
    C. Patel, L. Castaneda, U. Frevert, L. Li, D.M. Kornhauser, D.W. Boulton, Single-dose pharmacokinetics and safety of saxagliptin in subjects with hepatic impairment compared with healthy subjects (Abstract 537-P). Diabetes 57(Suppl. 1), A160 (2008)Google Scholar
  43. 43.
    E.M. Migoya, C.H. Stevens, A.J. Bergman, W.L. Luo, K.C. Lasseter, S.C. Dilzer, M.J. Davies, J.A. Wagner, G.A. Herman, Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Can J Clin Pharmacol 16, e165–e170 (2009)PubMedGoogle Scholar
  44. 44.
    Y.L. He, R. Sabo, J. Campestrini, Y. Wang, M. Ligueros-Saylan, K.C. Lasseter, S.C. Dilzer, D. Howard, W.P. Dole, The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin. Eur. J. Clin. Pharmacol. 63, 677–686 (2007)PubMedCrossRefGoogle Scholar
  45. 45.
    Karim A, Fleck P, Dorsey D et al. Single-dose pharmacokinetics of alogliptin benzoate (SYR-322), a highly selective dipeptidyl peptidase-4 inhibitor, in subjects with moderate hepatic impairment (Abstract). J Clin Pharmacol 2007; 47: Abstract 107Google Scholar
  46. 46.
    A. Flint, K. Nazzal, P. Jagielski, C. Hindsberger, M. Zdravkovic, Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide. Br. J. Clin. Pharmacol. 70(6), 807–814 (2010)PubMedCentralPubMedCrossRefGoogle Scholar
  47. 47.
    Cooper M, von Eynatten M, Emser A, Patel S, Woerle HJ. Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes With or Without Renal Function Decline: Results From a Global Phase 3 Program. Poster: 1068-P, 71st Scientific Sessions of the American Diabetes Association, San Diego, California, June 24–28, 2011Google Scholar
  48. 48.
    S. Del Prato, A.H. Barnett, H. Huisman, D. Neubacher, H.J. Woerle, K.A. Dugi, Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes. Metab. 13(3), 258–267 (2011)PubMedCrossRefGoogle Scholar
  49. 49.
    u Taskinen, J. Rosenstock, I. Tamminen, R. Kubiak, S. Patel, K.A. Dugi, H.J. Woerle, Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes. Metab. 13(1), 65–74 (2011)PubMedCrossRefGoogle Scholar
  50. 50.
    D.R. Owens, R. Swallow, K.A. Dugi, H.J. Woerle, Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet. Med. 28(11), 1352–1361 (2011)PubMedCrossRefGoogle Scholar
  51. 51.
    McGill Janet b., Lance Sloan, Jennifer Newman, Sanjay Patel, Christophe Sauce, Maximilian Von Eynatten, Hans-Juergen Woerle, Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment. Diabetes Care Publish Ahead of Print, published online October 1, 2012Google Scholar
  52. 52.
    J.C. Chan, R. Scott, Arjona Ferreira JC, Sheng D, Gonzalez E, Davies MJ, Stein PP, Kaufman KD, Amatruda JM, Williams-Herman D. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes. Metab. 10, 545–555 (2008)PubMedCrossRefGoogle Scholar
  53. 53.
    V. Lukashevich, A. Schweizer, Q. Shao, P.H. Groop, W. Kothny, Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes. Metab. 13(10), 947–954 (2011)PubMedCrossRefGoogle Scholar
  54. 54.
    V. Lukashevich, A. Schweizer, J.E. Foley, S. Dickinson, P.H. Groop, W. Kothny, Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment. Vasc Health Risk Manag. 9, 21–28 (2013)PubMedCentralPubMedCrossRefGoogle Scholar
  55. 55.
    Kothny W, Schweizer A, Naik R, Groop PH, Shao Q, Lukashevich V. Comparison of vildagliptin with placebo in a 24-week study of 221 patients with type 2 diabetes and severe renal impairment (eGFR < 30). EASD 2011Google Scholar
  56. 56.
    M. Nowicki, I. Rychlik, H. Haller, M.L. Warren, L. Suchower, Gause-Nilsson I; D1680C00007 Investigators. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes. Metab. 13(6), 523–532 (2011)PubMedCrossRefGoogle Scholar
  57. 57.
    M. Nowicki, I. Rychlik, H. Haller, M. Warren, L. Suchower, I. Gause-Nilsson, K.M. Schützer, Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int. J. Clin. Pract. 65(12), 1230–1239 (2011)PubMedCrossRefGoogle Scholar
  58. 58.
    Y. Nakamura, M. Inagaki, T. Shimizu, K. Fujita, M. Inoue, H. Gotoh, K. Oguchi, Y. Goto, Long-Term Effects of Alogliptin Benzoate in Hemodialysis Patients with Diabetes: A 2-year Study. Nephron Clin Pract 123, 46–51 (2013). doi: 10.1159/00035167 PubMedCrossRefGoogle Scholar
  59. 59.
    Ahrén B, Leguizamo Dimas A, Miossec P, Saubadu S, Aronson R. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care. 2013 Sep;36(9):2543-50. doi:  10.2337/dc12-2006. Epub 2013 Mar 27
  60. 60.
    Sloan L, Newman J, Sauce C, von Eynatten M, Patel S, Woerle HJ. Safety and Efficacy of Linagliptin in Type 2 Diabetes Patients With Severe Renal Impairment. Poster: 413-PP, 71st Scientific Sessions of the American Diabetes Association, San Diego, California, June 24–28, 2011Google Scholar
  61. 61.
    H. Yanai, H. Adachi, H. Hamasaki, Y. Masui, R. Yoshikawa, S. Moriyama, S. Mishima, A. Sako, Effects of 6-month sitagliptin treatment on glucose and lipid metabolism, blood pressure, body weight and renal function in type 2 diabetic patients: a chart-based analysis. J Clin Med Res. 4(4), 251–258 (2012)PubMedCentralPubMedGoogle Scholar
  62. 62.
    W. Kothny, Q. Shao, P.H. Groop, V. Lukashevich, One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes. Metab. 14(11), 1032–1039 (2012)PubMedCrossRefGoogle Scholar
  63. 63.
    Russo E, Penno G, Del Prato S. Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin. Diabetes Metab Syndr Obes. 2013 Apr 24;6:161-70. doi:  10.2147/DMSO.S28951. Print 2013
  64. 64.
    Alogliptin. Highlights of prescribing information http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022271s000lbl.pdf. Last access January 8, 2014
  65. 65.
    Pendergrass M, Fenton C, Haffner SM, Chen W. Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis. Diabetes Obes Metab 2012, Jan 23Google Scholar
  66. 66.
    U.S. Food and Drug Administration. Information for healthcare professionals; reports of altered kidney function in patients using exenatide (marketed as Byetta). Available from http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm113705.htm. Accessed June 09, 2013
  67. 67.
    W.J. Weise, M.S. Sivanandy, C.A. Block, R.J. Comi, Exenatide-associated ischemic renal failure. Diabetes Care 32, 22–23 (2009)CrossRefGoogle Scholar
  68. 68.
    H. Nandakoban, T.J. Furlong, J.R. Flack, Acute tubulointerstitial nephritis following treatment with exenatide. Diabet. Med. 30(1), 123–125 (2013). doi: 10.1111/j.1464-5491.2012.03738.x PubMedCrossRefGoogle Scholar
  69. 69.
    Y. Kaakeh, S. Kanjee, K. Boone, J. Sutton, Liraglutide-induced acute kidney injury. Pharmacotherapy 32(1), e7–e11 (2012)PubMedCrossRefGoogle Scholar
  70. 70.
    N.R. Pinelli, C.L. Moore, S. Tomasello, Incretin-based therapy in chronic kidney disease. Adv Chronic Kidney Dis 17(5), 439–449 (2010)PubMedCrossRefGoogle Scholar
  71. 71.
    M.C. Riddle, R. Aronson, P. Home, M. Marre, E. Niemoeller, P. Miossec, L. Ping, J. Ye, J. Rosenstock, Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 36(9), 2489–2496 (2013)PubMedCrossRefGoogle Scholar
  72. 72.
    J. Rosenstock, D. Raccah, L. Korányi, L. Maffei, G. Boka, P. Miossec, J.E. Gerich, Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care 36(10), 2945–2951 (2013)PubMedCrossRefGoogle Scholar
  73. 73.
    Lixisenatide. Summary of product characteristics. http://www.ema.europa.eu/docs/it_IT/document_library/EPAR_Product_Information/human/002445/WC500140401.pdf. Last access January 8, 2014
  74. 74.
    Kothny W, Schweizer A, Naik R, Groop PH, Shao Q, Lukasevich V. Comparison of vildagliptin with placebo in a 24-week study of 221 patients with type 2 diabetes and severe renal impairment (eGFR < 30). Diabetologia Volume 54 (1) Springer Journals – Sep 1, 2011. A(819)Google Scholar
  75. 75.
    D.J. Cuthbertson, A. Irwin, C.J. Gardner, C. Daousi, T. Purewal, N. Furlong, N. Goenka, E.L. Thomas, V.L. Adams, S.P. Pushpakom, M. Pirmohamed, G.J. Kemp, Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS ONE 7(12), e50117 (2012)PubMedCentralPubMedCrossRefGoogle Scholar
  76. 76.
    Ali S, Fonseca V. Saxagliptin overview: special focus on safety and adverse effect. Expert Opinion on Drug Safety Jan 2013, Vol. 12, No. 1: 103–109Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Carlo B. Giorda
    • 1
    Email author
  • Elisa Nada
    • 2
  • Barbara Tartaglino
    • 2
  1. 1.Metabolism and Diabetes UnitASL TO5Regione PiemonteItaly
  2. 2.Chaira Medica AssociationChieriItaly

Personalised recommendations